# Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage Trial

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/obesityweek/123955) · 2026-11-18 · Medicine
Page: https://themorning.science/story/quadruple-agonist-reduced-weight-without-major-muscle-loss-in-mid-stage-trial-6fe74fa8f2ef9058
Kind: research · Impact: medium

## In brief

- A randomized phase II trial of an investigational oral quadruple receptor agonist was presented at ObesityWeek in National Harbor, Md.
- The trial reported substantial weight loss with preservation of lean mass.
- By week 13, the two highest tested doses had produced the reported weight loss, according to the source excerpt, which is truncated.

## Why it matters

If later trials confirm that weight loss can occur without major muscle loss, it could change how clinicians weigh the benefits and risks of obesity drugs. These are mid-stage results for an investigational drug, so they are early evidence.

## Timeline

- 2026-11-18: Phase II trial results presented at ObesityWeek in National Harbor, Md.

## Coverage

- [Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage Trial](https://www.medpagetoday.com/meetingcoverage/obesityweek/123955) — MedPageToday.com - medical news for physicians, 2026-11-18

Tags: obesity, weight loss, clinical trial, oral drug, lean mass

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
